Wells Fargo & Company Rani Therapeutics Holdings, Inc. Transaction History

Wells Fargo & Company

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 10, 2024	BUY	$2.98 - $3.8 $2 - $3	1 Added 0.98%	103 $0
Q4 2023 Feb 09, 2024	BUY	$1.85 - $3.67 $14 - $29	8 Added 8.51%	102 $0
Q3 2023 Nov 13, 2023	BUY	$2.17 - $4.44 $36 - $75	17 Added 22.08%	94 $0
Q2 2023 Aug 15, 2023	BUY	$3.92 - $5.58 $19 - $27	5 Added 6.94%	77 $0
Q1 2023 May 12, 2023	BUY	$5.07 - $6.89 $10 - $13	2 Added 2.86%	72 $0
Q4 2022 Feb 13, 2023	BUY	$5.51 - $10.02 $11 - $20	2 Added 2.94%	70 $0
Q3 2022 Nov 14, 2022	SELL	$8.23 - $12.4 $102,562 - $154,528	-12,462 Reduced 99.46%	68 $1,000
Q2 2022 Aug 12, 2022	BUY	$8.0 - $14.25 $456 - $812	57 Added 0.46%	12,530 $129,000
Q1 2022 May 16, 2022	BUY	$12.21 - $23.14 $152,283 - $288,602	12,472 Added 1247200.0%	12,473 $168,000
Q4 2021 Feb 14, 2022	SELL	$16.09 - $35.0 $627 - $1,365	-39 Reduced 97.5%	1 $0
Q3 2021 Nov 15, 2021	BUY	$10.7 - $21.43 $428 - $857	40 New	40 $1,000

5.77M

2.5K

2.2K

Ticker RANI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 24,492,000
Market Cap $35.8M
Description
Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company that develops orally administered biologics. The company develops the RaniPill capsule, a platform that is intended to replace subcutaneous or IV injection of biologics with oral dosing. Its product pipeline includes RT-101, an octreotide, which has completed P...

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

Stay updated on Wells Fargo & Company with notifications on news.